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Transplacental antibody transfer from mother to fetus provides protection from infection
in the first weeks of life, and the four different subclasses of IgG (IgG1, IgG2,
IgG3, and IgG4) have diverse roles in protection against infection. In this study, we
evaluated concentrations and transplacental transfer ratios of the IgG subclasses in
a healthy UK-based cohort of mother-cord pairs, and investigated associations with
maternal, obstetric, and fetal factors. In agreement with previous studies, we found
a strong association between maternal and cord IgG for all subclasses. We report
a transfer efficiency hierarchy of IgG1>IgG3>IgG4=IgG2 in our study population,
and our review of the literature demonstrates that there is no consensus in the
hierarchy of subclass transfer, despite the commonly made statement that the order
is IgG1>IgG4>IgG3>IgG2. We report additional data regarding negative associations
between elevated maternal IgG concentrations and maternal/cord transfer ratios, finding
an effect on IgG1, IgG2, and IgG3 subclasses. Levels of IgG subclasses were the
same between venous and arterial blood samples from the umbilical cord, but there
was a significantly higher level of total IgG in arterial blood. We found no correlation
between placental FcRn protein levels and IgG transfer in our cohort, suggesting that
IgG is the main determinant of observed differences in transplacental transfer ratios at
term. Neonatal IgG1 and IgG4 levels were increased with later gestation at delivery,
independent of any increase in transplacental transfer, indicating that the benefit of
later gestation is through accumulation of these subclasses in the fetus. Neonatal IgG2
levels and transfer ratios were reduced in rhesus-negative pregnancies, suggesting
that administered anti-D antibodies may compete for transplacental transfer of this
subclass. Maternal influenza vaccination resulted in elevatedmaternal and neonatal levels
of IgG4, whereas maternal Tdap vaccination had no impact on neonatal levels of the
subclasses, nor transfer. However, within Tdap vaccinated pregnancies, later gestation at
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Tdap vaccination was associated with higher transplacental transfer. Our study provides
information regarding levels and transfer of IgG subclasses in healthy term pregnancies
and demonstrates the importance of recording detailed clinical information in studies of
antibody transfer, including parity, ethnicity, and timing of maternal vaccine delivery.
Keywords: pregnancy, placenta, maternal vaccination, antibody, IgG, immunology, infection, neonatal
INTRODUCTION
The neonatal period is a high-risk period for infectious
diseases. Neonates are afforded some protection through
passive immunity provided by maternal immunoglobulin (IgG)
actively transferred across the placenta during pregnancy. This
phenomenon has enabled maternal vaccination strategies aimed
at boosting fetal levels of antigen-specific IgG for diseases
associated with high neonatal mortality and morbidity. Maternal
administration of tetanus and pertussis vaccines have both been
highly successful at reducing rates of neonatal disease (1–4).
Transfer of IgG across the placental barrier is thought to
involve interaction between IgG and the neonatal Fc receptor
(FcRn) in the placental syncytiotrophoblast (5). FcRn is a
heterodimer, consisting of an integral membrane glycoprotein
which is structurally related to an MHC class I molecule and
β2-microglobulin, and is capable of binding the IgG Fc region
(6). The binding of FcRn to IgG only occurs at acidic pH 6 (7).
For FcRn to bind IgG, IgG must therefore be taken up from the
maternal circulation by the syncytiotrophoblast into endosomes
which undergo acidification. The endosomes then fuse with the
fetal side of the syncytiotrophoblast, leading to an increase in the
pH, and the release of IgG into the stroma (8). It is not currently
known how IgG crosses the stroma and the second placental
barrier—the fetal endothelium—but FcRn may also be present
in this endothelial layer (9). Other receptors or Fc-binding
proteins found in the placenta could also be involved (6). More
detail on the process of IgG transfer is available in our recently
published review on FcRn-mediated transplacental antibody
transfer (10).
IgG is divided into four subclasses, which cross the placenta
with differential efficiency. The issue of transplacental transfer
of the IgG subclasses is important, as they play diverse roles
in immunity, and their production is differentially induced by
distinct pathogens and vaccines [reviewed in (11)]. A number
of papers and reviews state that the order of transplacental
transfer is IgG1>IgG4>IgG3>IgG2, and that IgG2 transfer
is “poor”. These usually reference one review (12) that has
a graph illustrating data from a single study (13). We have
identified 17 papers that have measured maternal and cord
levels of the four IgG subclasses (13–29) (Figure 1). Calculating
the mean from these papers produces transfer ratios of 1.36
for IgG1, 0.97 for IgG2, 1.12 for IgG3, and 1.12 for IgG4,
although the high inter-study variation in both transfer ratios
and the transfer hierarchy of the subclasses makes this average
an oversimplification. Of the 17 papers, only seven (41%) report
the transfer hierarchy of IgG1>IgG4>IgG3>IgG2. The reasons
for these varying reports could be due to many differences in
study populations including ethnicity, parity, BMI, placental
weight, birth weight, gestation at birth, as well as maternal
antigen exposure (through vaccination or infection) modifying
antibody phenotype (including subclasses, antigen-specificity,
and glycosylation).
Many previous studies of placental antibody transfer have
been relatively small and often have not interrogated the
effect of clinical variables other than gestation at delivery.
Later gestation at delivery is associated with an increase in
maternal to cord transfer ratios and in concentrations of
antibody in cord blood (11, 30–32). However, several additional
maternal and fetal factors have the potential to impact on
placental antibody subclass transfer. This includes fetal sex,
Rhesus status (and associated anti-D antibody administration),
maternal vaccination, BMI, parity and ethnicity, among others.
It is important to understand the role of these factors when
performing maternal vaccination studies in diverse patient
populations. We performed IgG subclass analysis on a large
number of maternal and cord blood samples, including an
assessment of the impact of maternal and fetal factors on IgG
subclass levels and transplacental transfer.
MATERIALS AND METHODS
Study Subjects and Sample Collection
Serum samples were obtained from 116 corresponding maternal
and–cord blood pairs, as part of twomaternal vaccination studies.
These studies were approved by Research Ethics Committee
(MatImms: REC 13/LO/1712. and COMET: REC 19/YH/0217)
and written informed consent was obtained from all participants.
Healthy women with singleton pregnancies with no known
complications nor chronic or acute diseases were recruited. All
pregnancies delivered at term (range 37+3 to 42+3). Detailed
clinical data including BMI, parity, age, ethnicity, gestation at
delivery, infant sex, birth weight, and maternal vaccination status
were recorded. Individualized birthweight centiles (IBC) were
calculated using GROW software (Perinatal Institute, version
8.0.4, gestation.net), which controls for maternal height, weight,
ethnicity, and parity, and sex and gestation at birth. Serum
samples were obtained from mothers near the time of birth
(between 1 day before delivery and 3 days after delivery), and
from the umbilical cord vein or artery within 1 h of delivery.
Where possible, blood was collected separately from both the
umbilical vein and the umbilical artery and this was recorded.
Blood was collected into serum-separating tubes (BD) and left to
clot for a minimum of 15min before spinning at 1900G for 10
min. Serum was aliquoted and stored at−80◦C.
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FIGURE 1 | Overview of studies investigating maternal to fetal transfer ratios of IgG subclasses. We identified 17 papers that measured paired maternal and cord
levels of all four IgG subclasses (13–22, 24–29). Studies had either employed radioimmunoassay, immunodiffusion, laser nephelometry or ELISA. The line graph
represents the mean to fetal transfer ratio on a log(2) axis. Levels >1 (above the dotted line) indicates higher levels in cord blood compared to maternal blood. The
dotted black line indicates the mean of the 16 studies. For Malek et al. (29) we only used the values from term pregnancies (37–41weeks). For two studies, we
performed ratio calculations based on reported maternal and cord concentrations (21, 29). For two other studies, values were calculated by reading from the
published graphs (13, 15). For Costa-Carvalho et al. (13) this required us to read the ratios from the summary graph produced in the review by Palmerio et al. (12). In
Hay et al. (28), the maternal levels of IgG1 were the lowest of all the other subclasses and maternal IgG2 was the highest (double the level of IgG1).
Immunoglobulin G (IgG) ELISAs
IgGs were measured using human Total IgG, IgG1, IgG2, IgG3,
and IgG4 uncoated ELISA kits (Invitrogen) according to the
manufacturer’s instructions. Absorbance was read at 450 nm
using a VersaMax ELISA microplate reader.
Western Blotting
Washed placental villous tissue was lysed in cold RIPA buffer
containing protease and phosphatase inhibitors (cOmpleteTM
Protease Inhibitor Cocktail and PhosSTOP; Roche), in Lysing
Prep D tubes (1.4mm ceramic spheres), using a FastPrep-24
machine. Following centrifugation, protein supernatants were
quantified by BCA assay (Pierce) using a VersaMax Microplate
reader (Molecular Devices). Protein was prepared in reducing
Laemmli SDS sample buffer (Alfa Aesar) and heated at 95◦C
for 5min. Equal amounts of protein (25 µg) were separated on
Bis-Tris gels and transferred onto PVDF membrane (iBLOT gel
transfer stacks; Invitrogen). Membranes were stained for total
protein using the MemCodeTM Reversible Protein Stain (Thermo
Scientific) following the manufacturer’s instructions. This kit
utilizes a high affinity protein stain which is compatible with
subsequent western blotting. Following staining, membranes
were imaged on the ImageQuant camera system (LAS 4000;
GE Healthcare) to enable normalization of subsequent specific
protein bands. This approach for normalization was employed
due to the high variability of common protein loading controls
in the placenta (33). After de-staining, membranes were blocked
for 1h (5% dry milk, 1% BSA), and probed with 0.1µg/ml anti-
FcRn antibody (SC B-8, Santa Cruz Biotechnology) overnight
at 4◦C. Bound antibody was detected through incubation
with 0.125µg/ml horseradish peroxidase (HRP)–conjugated goat
anti-rabbit secondary antibody (Dako). Finally, membranes were
developed using ECL Prime Western blotting detection reagent
(Amersham) and Hyperfilm (Amersham). FcRn levels relative to
total protein was determined by densitometry (ImageJ).
Statistical Analysis
Statistical analyses were performed in GraphPad Prism v8.0 and
STATA v16. IgG concentrations were log transformed (natural
Log) prior to analysis to achieve normality. Maternal to fetal
transfer ratios were calculated by dividing the IgG concentration
in cord blood, by the IgG concentration in paired maternal
blood. These ratios were then log(2) transformed prior to
analysis. Comparison of transfer ratios was performed using
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TABLE 1 | Maternal and infant characteristics.
Maternal age, years (mean and range) 33 (20–45)
Maternal height, cm (mean and range) 165 (135–181)
Maternal weight, kg (mean and range) 67.1 (48.2–111)
BMI (mean and range) 24.6 (17.9–38.9)
Blood group
A (n and %) 43 (37%)
B (n and %) 14 (12%)
AB (n and %) 2 (1.7%)
O (n and %) 57 (49%)
Rhesus + (%) 87.9%
Primiparous (%) 58.62%
Non-white ethnicity (%) 41.4%
Tdap vaccinated (%) 61.2%
Gestation at Tdap (weeks) 30.8 (20–39)
Flu vaccinated (%) 50.0%
Gestation at flu (weeks) 24.8 (5–39)
Vaginal delivery (%) 44.0%
Delivery with labor (%) 53.4%
Gestation at delivery (mean and range) 40.1 (37+3–42+3)
Male sex baby (%) 51.7%
Birth weight, kg (mean and range) 3.45 (2.32–4.45)
RepeatedMeasures OneWay ANOVA andHolm Sidak’s multiple
comparisons test. We looked at the effect of the following clinical
parameters on antibody transfer: maternal age, maternal body
mass index (BMI), rhesus status, ethnicity, parity, vaccination
status (tetanus, diphtheria, acellular pertussis and inactivated
poliomyelitis [Tdap/IPV] combination vaccination, or seasonal
influenza vaccination), gestational age at vaccination, gestational
age at delivery, infant sex, and individualized birth ratio (IBC).
For ethnicity, we had subjects in 14 groups with small numbers in
many; we therefore collapsed the groups into white (white British,
white Irish and any other white background; 0) and non-white
(black/black British, Asian/Asian British, mixed, and “other”; 1)
to enable analysis. For parity, we combined those with parity 1–
3 into one “parous” group (coded 1) and compared these to the
primiparous group (no previous live births; 0).
Unadjusted and adjusted effects were estimated by simple and
multiple linear regression models in Stata v16. Significance was
assessed at the 5% level. All covariates that were significant at the
5% level entered the multiple regression models.
RESULTS
Maternal and Cord Blood IgG Subclass
Profiles and Transfer Ratios
Clinical characteristics of the study subjects are shown in Table 1.
As mothers were bled at varying times pre-/post-delivery, we
checked that this did not impact onmaternal IgG concentrations,
which would bias the calculation of transfer ratios. Our study
subjects were bled 1 day before delivery (n = 7), on the
day of delivery (n = 78), within ½ day of delivery (n = 2),
within 1 day (n = 20), 2 days (n = 5), or 3 days (n = 3).
There was no significant effect of timing of maternal bleed and
maternal IgG concentrations (Supplemental Figure 1). Maternal
and cord blood exhibited similar IgG subclass profiles, with
relative abundance highest for IgG1, followed by IgG2, IgG3,
then IgG4 in mothers, as well as their infants (Figure 2A). The
maternal to fetal transfer ratio of IgG1 (1.538) was significantly
higher than the other subclasses (Figure 2B). IgG3 also exhibited
a small, but significantly higher transfer ratio (1.040) than both
IgG2 (0.9326) and IgG4 (0.9330). When transfer ratios were
normalized to total IgG levels in mothers, as a measure of
relative transfer efficiency, a similar pattern of transfer was
observed, although IgG3 was no longer significantly higher than
IgG4 (Figure 2C). When transfer ratios were compared between
pregnancies between 37+3 and 42+3 weeks gestation, similar
relative transfer ratios were also observed, with significantly
higher IgG1 transfer than the other subclasses at all gestations
(Figure 2D). Paired comparison revealed significantly higher
levels of total IgG and IgG1, and significantly lower levels of IgG2
and IgG4 in cord blood serum compared to matched maternal
serum (Figure 2E). IgG3 was not significantly different between
mothers and infants. The percentage of mother-cord pairs with
transfer >1 was 83.6% for IgG1, 49.1% for IgG3, and 31.8%
for both IgG2 and IgG4. Correlation plots of maternal and
cord IgG levels show a positive correlation between maternal
and cord antibody for total IgG and all IgG subclasses. Within
the subclasses, the strongest correlation between maternal and
cord levels is for IgG4, with the weakest correlation for IgG2
(Figure 2F). Additional descriptive statistics on the transfer of
the subclasses is provided in Supplemental Table 1.
Maternal Antibody Concentrations Are
Negatively Correlated With Maternal to
Fetal Transfer Ratios of IgG Subclasses
As maternal levels of antigen-specific antibodies have been
associated with reduced placental transfer ratios (11, 34),
we investigated the association between maternal levels of
antibody subclasses and transfer ratios (Figure 3). Maternal
concentrations of total IgG, IgG1, and IgG3 were negatively
associated with the transfer ratios of total IgG. Total IgG, IgG1,
IgG2, and IgG3 were negatively associated with transfer of IgG1–
IgG3. Maternal concentrations of IgG4 were only negatively
associated with the transfer ratios of IgG1.
Maternal to Fetal Transfer Ratios Are
Largely Unaffected by Sampling of the
Umbilical Artery or Umbilical Vein
As the umbilical vein represents oxygenated blood flowing from
the placenta, and the umbilical arteries represent deoxygenated
blood flowing from the fetus (Figure 4A), we investigated
whether any differences could be observed in blood sampled from
these two vessels. Although total IgG levels were significantly
higher in arterial blood, this difference was not borne out in
the analysis of the IgG subclasses (Figure 4B). Both maternal:
umbilical vein IgG levels, and maternal: umbilical artery IgG
levels were positively correlated (Figure 4C).
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FIGURE 2 | Maternal and cord blood IgG subclass profiles and transfer ratios. (A) IgG1-4 concentrations (µg/ml) in maternal (M) and cord (C) blood on a log(2) axis.
(B) Maternal to fetal transfer ratios of IgG1-4 represented on log(2) scale. Values >1 indicates higher levels in cord blood, indicated by dashed line. Analysis performed
on log(2) transformed transfer ratios, using Repeated Measures One Way ANOVA and Holm Sidak’s multiple comparisons test. (C) Maternal to fetal transfer ratios of
IgG1–4 normalized to levels of total IgG in maternal blood as an indicator of transfer efficiency. Analysis by Repeated Measures One Way ANOVA and Holm Sidak’s
(Continued)
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FIGURE 2 | multiple comparisons test. (D) Maternal to fetal transfer ratios of IgG1–4 represented on log(2) scale broken down by gestational age at delivery. Values
>1 indicates higher levels in cord blood, indicated by dashed line. Analysis performed on log(2) transformed transfer ratios, using Repeated Measures One Way
ANOVA and Holm Sidak’s multiple comparisons test. Hierarchy of IgG1>IgG3>IgG2>IgG4 for 37–38 weeks and 40+ weeks gestation. Hierarchy of
IgG1>IgG3>IgG4>IgG2 for 39 weeks gestation. (E) Dot-line plots showing the relationship between IgG concentrations in maternal and cord pairs. Groups
compared by paired t test on nLog-transformed data. (F) Correlations between maternal and cord IgG concentrations. Lines indicate simple linear regression. nLog
values analyzed by Pearson r-test. N = 114 maternal and cord pairs. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
FIGURE 3 | Impact of maternal IgG concentrations on the rate of maternal to fetal IgG transfer. Heatmap with overlaid scatterplots showing the effect of increasing
concentrations of maternal IgG (X axis) on the transfer rates of total IgG (TIgG) and IgG1–4 from mother to fetus (Y axis, Log2 scale). Horizontal dashed line represents
equal levels between mother and fetal circulations. Correlations between nlog-transformed maternal IgG concentrations and log(2)-transformed transfer ratios were
analyzed by Spearman’s rank correlation coefficient. The scale on the right indicates the color associated with the Spearman r-values. Inverse correlations are
depicted in the darker shades, and weaker and no associations are depicted in lighter shades toward yellow. The lines on the scatterplots indicate simple linear
regressions. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05.
Correlation Between Placental FcRn
Expression and Transfer of IgG Subclasses
Transplacental antibody transfer across the synctytiotrophoblast
layer of the placenta is mediated through interaction with the
neonatal Fc receptor [FcRn; reviewed in (10)]. To investigate
whether inter-individual differences in IgG subclass transfer
are due to differences in FcRn levels in the placenta,
western blotting of paired placental samples was performed
(Figure 5). With the set of paired samples available (n =
20), no association was detected between placental FcRn
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FIGURE 4 | Comparison of IgG subclasses in umbilical cord vein and arterial blood. (A) Illustration of the placental circulation, showing the umbilical arteries bringing
deoxygenated blood from the placenta to the fetus, and oxygenated blood returning to the fetus from the placenta via the umbilical vein. (B) Dot-line plots showing
the relationship between IgG concentrations in paired umbilical cord vein and artery serum samples (n = 30). Groups compared by paired t-test on nLog-transformed
data. **p < 0.01 (C) Correlations between maternal and cord IgG concentrations. Lines indicate simple linear regression. nLog values analyzed by Pearson r-test. N =
30 matched umbilical vein/umbilical artery serum pairs and 20 matched maternal/umbilical vein/umbilical artery serum trios.
levels and the transfer ratio of total IgG nor subclasses 1–4
(Figure 5C).
Investigation of Clinical Variables
Associated With Levels and Transfer of
IgG: Unadjusted Effects
Unadjusted analyses were performed to explore relationships
between clinical variables and maternal and cord IgG
concentrations, as well as the maternal to fetal transfer of IgG
subclasses (Tables 2–4). Increased maternal age was associated
with lower total IgG in mothers (p = 0.042; Table 2), but had no
effect on cord levels (Table 3) nor transfer (Table 4). Non-white
women had higher levels of total IgG, IgG2, and IgG3 (p= 0.034,
0.019, and 0.024; Table 2). There was no corresponding increase
in infant IgG levels, and the calculated transfer ratios of IgG3 in
these pregnancies was significantly lower (p = 0.004; Table 4).
Parous women had higher levels of total IgG (p = 0.004) and
IgG1 (p = 0.034) compared to primiparous. The transfer ratios
of total, IgG1 and IgG3 in these pregnancies was significantly
lower (p = 0.023, 0.001, and 0.001; Table 4), resulting in no
corresponding increase in infant IgG levels (Table 3). Although
maternal rhesus status had no effect on maternal IgG levels,
rhesus negative pregnancies were associated with lower transfer
of IgG2 (p = 0.048) and a corresponding lower level of IgG2 in
cord blood (p = 0.047) compared to rhesus positive pregnancies.
Later gestation at delivery was associated with lower maternal
levels of total IgG (p = 0.018) and higher IgG4 (p = 0.003).
Transfer ratios were higher with later gestation at delivery for
total IgG, IgG1, and IgG3 (p = 0.002, 0.04, and 0.015; Table 4).
The outcome of later gestation at delivery was higher neonatal
levels of IgG1 and IgG4 (p= 0.013, 0.001;Table 3). Neonates with
higher birth centiles had lower levels of total IgG and IgG2 (p =
0.004, 0.042;Table 3). Pregnancies with higher centile infants also
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FIGURE 5 | Correlation of placental FcRn levels with transfer of IgG subclasses. (A) Western blot for FcRn in lysates of placental villous tissue. Proteins were prepared
under reducing denaturing conditions. Top labels indicate gestational age of the sample in weeks+days. (B) Total protein stain (left panel) and densitometry analysis
(right panel). (C) Correlation between placenta FcRn protein levels (normalized to total protein stain) and maternal to fetal IgG transfer ratios (log(2) transformed)
analyzed by Spearman’s rank correlation coefficient. All correlations non-significant at p > 0.05 level (Total IgG p = 0.51, Spearman r 0.156; IgG1 p = 0.80, r =
−0.062; IgG2 p = 0.54, r = 0.146; IgG3 p = 0.67, r = −0.101; IgG4 p = 0.26, r = −0.266). N = 20.
had lower maternal to fetal transfer of IgG1 (p= 0.032) and IgG4
(p = 0.015; Table 4). Maternal BMI and sex of the neonate had
no impact on any variables.
Impact of Maternal Tdap/IPV and Influenza
Vaccination on IgG Subclass Levels and
Transfer
Sixty-one percent of our cohort received Tdap vaccination
in pregnancy, and 50% received seasonal influenza vaccine
(Table 1). Tdap vaccination status had no effect on maternal or
cord IgG concentrations nor IgG transfer. Influenza vaccination
was associated with higher IgG4 in mothers (p = 0.038; Table 2)
and neonates (p = 0.019; Table 3), with no impact on transfer
ratios (Table 4).
The gestation at Tdap vaccination was positively correlated
with maternal to fetal transfer for IgG1 (p = 0.001), IgG2
(p = 0.007), IgG3 (p = 0.006), and IgG4 (p = 0.004;
Table 4, Figure 6A). There was no association between timing
of Tdap and maternal nor cord IgG concentrations (Tables 2,
3, Figure 6B). Later gestation at influenza vaccination was
associated with higher levels of total IgG in mums (p = 0.012;
Table 2), but had no effect on neonatal levels nor transfer. The
transfer ratio of IgG3was lower with later gestation at vaccination
(p= 0.013; Table 4).
Adjusted Effects Associated With Transfer
of IgG Subclasses
We next performed multiple regression analyses that included
the variables that were found to be significant at the 5% level in
our unadjusted analyses (Tables 2–4).
In the adjusted analysis, levels of total IgG in maternal
serum was associated with both parity and maternal age, but
not with gestation at delivery nor ethnicity (Table 5). Parous
women had higher levels of total IgG than primiparous women
(p = 0.015), and older women had lower levels of total IgG
(p = 0.018), after adjusting for gestation at delivery and for
ethnicity. Parous pregnancies had lower transfer ratios of IgG1
(p = 0.006), after adjusting for gestation at delivery and birth
centiles. Later gestation at delivery was associated with higher
transfer ratios of total IgG and IgG3 (p = 0.008). IgG3 transfer
was also significantly lower in pregnancies of non-white women
(p= 0.012).
We investigated the association between the clinical variables
in these models. Parity was associated with gestation at birth (p
= 0.019), with the individualized birth weight centile (IBC; p =
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TABLE 2 | Unadjusted effects of clinical parameters on maternal antibody concentrations using simple linear regression based on n = 106 for total IgG and n = 116 for
IgG subclasses.
Variable Antibody Coefficient Standard error p-value 95% CI
Maternal age
(years)
Total −0.014 0.007 0.042 −0.027, −0.001
IgG1 −0.013 0.012 0.275 −0.037, 0.011
IgG2 −0.007 0.011 0.546 −0.029, 0.015
IgG3 0.012 0.015 0.401 −0.017, 0.041
IgG4 −0.020 0.029 0.484 −0.077, 0.037
Maternal BMI Total 0.008 0.008 0.305 −0.007, 0.023
IgG1 −0.004 0.014 0.759 −0.032, 0.023
IgG2 −0.003 0.013 0.815 −0.028, 0.022
IgG3 0.015 0.017 0.368 −0.018, 0.048
IgG4 −0.007 0.033 0.826 −0.073, 0.058
Maternal ethnicity
(white = 0; non-white = 1)
Total 0.139 0.065 0.034 0.011, 0.268
IgG1 0.170 0.114 0.141 −0.057, 0.396
IgG2 0.247 0.104 0.019 0.041, 0.452
IgG3 0.314 0.138 0.024 0.042, 0.587
IgG4 −0.065 0.277 0.815 −0.614, 0.484
Parity
(primiparous = 0; parous = 1)
Total 0.188 0.063 0.004 0.062, 0.314
IgG1 0.243 0.113 0.034 0.019, 0.467
IgG2 0.187 0.105 0.077 −0.020, 0.394
IgG3 0.263 0.139 0.061 −0.012, 0.537
IgG4 0.158 0.277 0.570 −0.390, 0.706
Rhesus status
(negative = 0; positive = 1)
Total 0.078 0.111 0.486 −0.142, 0.298
IgG1 0.112 0.174 0.523 −0.233, 0.457
IgG2 0.072 0.161 0.655 −0.246, 0.390
IgG3 0.204 0.212 0.339 −0.216, 0.624
IgG4 −0.441 0.418 0.292 −1.267, 0.385
Gestation at delivery
(weeks)
Total −0.068 0.028 0.018 −0.124, −0.012
IgG1 0.026 0.051 0.605 −0.074, 0.127
IgG2 −0.013 0.047 0.779 −0.106, 0.079
IgG3 −0.010 0.062 0.874 −0.132, 0.113
IgG4 0.361 0.117 0.003 0.129, 0.593
Sex of baby
(male = 0; female = 1)
Total −0.018 0.065 0.780 −0.148, 0.111
IgG1 0.033 0.114 0.775 −0.193, 0.258
IgG2 0.093 0.104 0.373 −0.113, 0.300
IgG3 −0.138 0.138 0.321 −0.411, 0.136
IgG4 0.248 0.272 0.365 −0.291, 0.787
Individualized birth ratio
(IBC)
Total −0.002 0.001 0.075 −0.004, 0.001
IgG1 0.0001 0.002 0.942 −0.004, 0.004
IgG2 −0.002 0.002 0.355 −0.005, 0.002
IgG3 0.003 0.002 0.263 −0.002, 0.008
IgG4 −0.003 0.005 0.544 −0.013, 0.007
Tdap maternal vaccination status
(non-vacc = 0; vacc = 1)
Total 0.003 0.067 0.966 −0.126, 0.135
IgG1 0.180 0.115 0.121 −0.049, 0.409
IgG2 0.035 0.107 0.742 −0.177, 0.248
IgG3 0.146 0.142 0.305 −0.135, 0.426
IgG4 −0.031 0.280 0.911 −0.586, 0.523
Tdap maternal vaccination timing
(gestational weeks)
Total −0.008 0.014 0.593 −0.036, 0.021
IgG1 −0.022 0.023 0.328 −0.068, 0.023
IgG2 −0.025 0.020 0.226 −0.066, 0.016
IgG3 0.003 0.027 0.919 −0.052, 0.058
IgG4 0.012 0.052 0.823 −0.093, 0.116
(Continued)
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TABLE 2 | Continued
Variable Antibody Coefficient Standard error p-value 95% CI
Flu maternal vaccination status
(non-vacc = 0; vacc = 1)
Total 0.032 0.065 0.621 −0.097, 0.161
IgG1 0.183 0.112 0.107 −0.040, 0.405
IgG2 −0.038 0.105 0.718 −0.245, 0.169
IgG3 0.090 0.138 0.519 −0.185, 0.364
IgG4 0.563 0.268 0.038 0.033, 1.094
Flu maternal vaccination timing
(gestational weeks)
Total 0.015 0.006 0.012 0.003, 0.026
IgG1 0.004 0.010 0.668 −0.016, 0.025
IgG2 0.017 0.009 0.057 −0.001, 0.035
IgG3 0.006 0.013 0.650 −0.020, 0.032
IgG4 −0.001 0.023 0.982 −0.046, 0.045
Bold values indicate p value < 0.05.
0.048), and with ethnicity (p= 0.003). Primiparous women were
more likely to be white (log-odds: 1.216; 95% CI: 0.408, 2.025),
had a higher mean gestation at delivery (coef: −0.497; 95% CI:
−0.908, −0.085), and their offspring had a lower mean birth
centile (coef: 10.423; 95% CI: 0.080, 20.766) compared to parous.
There was no association between maternal age and parity,
ethnicity nor gestation at delivery. Ethnicity was also associated
with gestation at delivery (p = 0.049); non-white women had a
lower mean gestation at birth compared to white women (coef:
−0.417; 95% CI:−0.832,−0.003).
DISCUSSION
We have performed a comprehensive analysis of maternal and
cord levels of the IgG subclasses and transplacental transfer in
a UK pregnancy cohort, and investigated their association with
maternal and fetal factors.
As previously observed, maternal concentrations of total IgG
and IgG subclasses were positively associated with umbilical
cord concentrations (Figure 2F) and negatively associated with
the maternal to fetal transfer ratios (Figure 3). As has been
previously well established, we found higher levels of total IgG
and IgG1 in cord blood compared to maternal blood, reflected
in a mean transfer ratio of 1.5 for IgG1. The transfer ratio of
the other subclasses was near to 1. In our study population the
transfer efficiency of the subclasses was IgG1>IgG3>IgG4=IgG2
(Figure 2B). The transfer ratio of IgG1 was significantly higher
than the ratios of the other subclasses at all gestations studied
(between 37 weeks and 42 weeks; Figure 2D), suggesting that
delivery post-dates does not affect the relative maternal/cord
ratios of IgG subclasses.
Maternal antibodies may compete for transplacental transfer
through their competition for placental FcRn, which binds
IgG in a 2:1 stoichiometry (35). Several studies have shown
that maternal total and antigen-specific IgG concentrations
are inversely correlated with maternal/cord ratios of total and
antigen-specific IgG (11, 17, 34, 36), supporting the concept
that antibody does not passively diffuse across the placenta
to reach equilibrium between maternal and fetal circulations,
but requires interaction with FcRn (and other potential Fc
receptors) for its transfer. There have been fewer studies of
the association between maternal levels of the IgG subclasses
and transplacental transfer. One study of placental malaria
and maternal hypergammaglobulinemia found an association
between maternal IgG levels >15g/L IgG and reduced transfer
of IgG1 and IgG2, with no effect on IgG3 and IgG4, compared
to maternal levels <15g/L (17). Our analysis performing
correlations on continuous data found a negative correlation
between maternal total IgG levels and the transfer ratios of total
IgG, IgG1, IgG2, and IgG3 subclasses in healthy pregnancy. We
also found that maternal concentrations of IgG1, IgG2, and IgG3
were negatively correlated with transfer ratios of total IgG and
IgG1–3. This suggests that the higher abundance IgG1, IgG2,
and IgG3 may all compete with their respective, and other
subclasses, for transfer across the placenta. Importantly, it must
be noted that within maternal blood, the concentrations of IgG2,
IgG3, and IgG4 are all correlated with IgG1. Thus, the effects
observed cannot be necessarily be attributed specifically to a
certain subclass, but could be driven by IgG1, which is highest
in abundance and transferred with the highest efficiency. With
that said, increased maternal IgG4 levels had limited correlation
with IgG transfer, and transfer of IgG4 was not correlated with
maternal levels of any antibody, even though maternal IgG4
levels are positively correlated with maternal IgG1. Furthermore,
IgG4 had the strongest correlation between maternal and cord
IgG concentrations, which altogether suggests that the transfer of
this subclass is least affected by changes in amounts of antibody
in the mother. The clinical significance of this phenomenon on
passive immunity in the neonate is likely to lie in the potential
impact on the transfer of antibodies against specific pathogens,
which should be explored.
It is important to note that this commonly utilized approach
of employing maternal/cord IgG ratios as an indicator of
transplacental transfer efficiency has its limitations. The relative
abundance between paired maternal-cord samples is not
necessarily a true reflection of transfer efficiency as this could be
biased by maternal concentrations, as well as the levels of IgG
recycling in fetal and maternal circulations. To partly address
this, we have shown that normalization of transfer ratios to total
IgG levels in maternal blood show the same pattern of differential
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TABLE 3 | Unadjusted effects of clinical parameters on umbilical cord antibody concentrations using simple linear regression based on n = 106 for total IgG and n = 116
for IgG subclasses.
Antibody Coefficient Standard error p-value 95% CI
Maternal age
(years)
Total −0.006 0.005 0.234 −0.016, 0.004
IgG1 −0.014 0.010 0.162 −0.034, 0.006
IgG2 −0.006 0.012 0.622 −0.029, 0.017
IgG3 0.013 0.013 0.312 −0.013, 0.040
IgG4 −0.018 0.032 0.577 −0.081, 0.045
Maternal BMI Total 0.004 0.006 0.443 −0.007, 0.015
IgG1 −0.009 0.011 0.445 −0.031, 0.014
IgG2 −0.002 0.013 0.876 −0.028, 0.024
IgG3 0.006 0.015 0.685 −0.024, 0.037
IgG4 −0.021 0.036 0.560 −0.093, 0.051
Maternal ethnicity
(white = 0; non-white = 1)
Total 0.054 0.047 0.255 −0.040, 0.148
IgG1 0.025 0.096 0.792 −0.165, 0.215
IgG2 0.163 0.111 0.142 −0.055, 0.382
IgG3 0.152 0.129 0.240 −0.103, 0.408
IgG4 0.008 0.304 0.978 −0.059, 0.611
Parity
(primiparous = 0; parous = 1)
Total 0.056 0.047 0.236 −0.037, 0.149
IgG1 −0.018 0.096 0.855 −0.208, 0.172
IgG2 0.031 0.112 0.784 −0.190, 0.252
IgG3 0.080 0.130 0.539 −0.177, 0.337
IgG4 −0.049 0.304 0.873 −0.651, 0.553
Rhesus status
(negative = 0; positive = 1)
Total 0.076 0.079 0.338 −0.081, 0.234
IgG1 0.177 0.144 0.223 −0.109, 0.462
IgG2 0.334 0.166 0.047 0.005, 0.662
IgG3 0.275 0.194 0.161 −0.111, 0.660
IgG4 −0.140 0.459 0.762 −1.049, 0.770
Gestation at delivery
(weeks)
Total 0.018 0.021 0.375 −0.023, 0.060
IgG1 0.104 0.041 0.013 0.022, 0.185
IgG2 0.059 0.049 0.229 −0.038, 0.156
IgG3 0.061 0.057 0.283 −0.051, 0.174
IgG4 0.429 0.128 0.001 0.176, 0.681
Sex of baby
(male = 0; female = 1)
Total 0.034 0.047 0.469 −0.059, 0.127
IgG1 0.000 0.096 0.999 −0.187, 0.187
IgG2 0.022 0.110 0.838 −0.195, 0.240
IgG3 −0.137 0.127 0.283 −0.390,0.115
IgG4 0.179 0.299 0.550 −0.413, 0.772
Individualized birth ratio
(IBC)
Total −0.002 0.001 0.004 −0.004, −0.001
IgG1 −0.003 0.002 0.099 −0.006, 0.001
IgG2 −0.004 0.002 0.043 −0.008, −0.000
IgG3 0.002 0.002 0.294 −0.002,0.007
IgG4 −0.008 0.005 0.139 −0.018, 0.003
Tdap maternal vaccination status
(non-vacc = 0; vacc = 1)
Total 0.047 0.048 0.332 −0.048, 0.141
IgG1 0.076 0.097 0.433 −0.116, 0.268
IgG2 −0.055 0.113 0.626 −0.278, 0.168
IgG3 0.165 0.130 0.207 −0.093, 0.423
IgG4 −0.140 0.307 0.649 −0.748, 0.468
Tdap maternal vaccination timing
(gestational weeks)
Total 0.016 0.009 0.079 −0.002, 0.034
IgG1 0.031 0.019 0.115 −0.008, 0.069
IgG2 0.024 0.023 0.296 −0.022, 0.070
IgG3 0.033 0.025 0.199 −0.018, 0.083
IgG4 0.090 0.059 0.133 −0.028, 0.208
(Continued)
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TABLE 3 | Continued
Antibody Coefficient Standard error p-value 95% CI
Flu maternal vaccination status
(non-vacc = 0; vacc = 1)
Total 0.005 0.047 0.912 −0.087, 0.098
IgG1 0.073 0.094 0.441 −0.114, 0.260
IgG2 0.002 0.110 0.989 −0.216, 0.219
IgG3 0.088 0.128 0.489 −0.164, 0.341
IgG4 0.696 0.292 0.019 0.117, 1.275
Flu maternal vaccination timing
(gestational weeks)
Total 0.009 0.004 0.056 −0.000, 0.018
IgG1 0.001 0.009 0.948 −0.017, 0.018
IgG2 0.005 0.009 0.619 −0.014, 0.023
IgG3 −0.006 0.012 0.631 −0.029, 0.018
IgG4 −0.002 0.024 0.934 −0.051, 0.047
Bold values indicate p value < 0.05.
transfer of the IgG subclasses (Figure 2C). We also show a
similar pattern of relative transfer ratios between 37 and 42 weeks
gestation. In vitro competition assays in human trophoblast or
non-human primate in vivo experiments with spike-in of IgG
subclasses are required to fully understand the competition for
transplacental transfer between the IgG subclasses. Nevertheless,
our data appears to support the current consensus that although
higher IgG levels in the mother will result in higher IgG
levels in the offspring, the relative transfer efficiency across
the placenta can be reduced when maternal concentrations
are elevated.
Given the limited capability for IgG production in the fetus,
the majority of antibody in the fetal circulation is maternal in
origin. We hypothesized that IgG levels in the umbilical arteries
(bringing deoxygenated blood from the fetus) would be higher
than levels in the umbilical vein (bringing freshly oxygenated
blood from the placenta). In contrast however, we found no
significant difference in the abundance of the IgG subclasses, and
only a slightly but significantly higher level of total IgG in the
umbilical artery. This was a surprising finding and could suggest
that there is greater hemodilution in venous blood compared to
arterial blood, or it could reflect efficient total antibody recycling
in the fetal circulation leading to higher levels in blood coming
from the fetus. No other study has investigated this to our
knowledge. It could be of interest to investigate FcRn levels
in the venous and arterial endothelium of the umbilical cord
and in the placental vasculature, as this is involved in antibody
recycling, thereby increasing half-life. It would also be of interest
to determine whether there are differences in the levels of
antigen-specific antibodies between venous and arterial umbilical
blood. This finding suggests that it is important that maternal
vaccination studies sample from the same umbilical/placental
vessels in case there are some as yet unidentified differences
between these biofluids.
For a subset of samples, we performed measurement of
FcRn in matched placenta. We found no significant correlation
between placental levels of FcRn and the transfer rates of total
IgG nor any of the antibody subclasses. One previous study has
correlated placental FcRn with transfer ratios, and concluded
that there was a positive association (37). However, this study
measured “the percentage of the total area in the placental tissue
with FcRn expression.” As the placental structure changes with
gestation, including the proportions of the different cell types,
measuring the percentage of tissue with FcRn content could
be interpreted as just a measurement of syncytiotrophoblast
surface area, rather than the concentration of FcRn within
this tissue. Our measurement of FcRn by western blotting
also has its limitations, given that it is measured in a mixed
homogenate of placental tissue. Importantly however, we only
looked at term placentas, which reduces the effect of gestational
changes in placental structure. Our data suggests that inter-
individual differences in transplacental transfer are mainly driven
by differences in IgG, however this question warrants further
investigation in a larger cohort, as well as investigation of other
Fc receptors.
Finally, we explored the potential clinical variables that may
impact on maternal and cord levels, and transfer ratios of total
IgG and the IgG subclasses. Only a few variables impacted on
the concentration of IgG in neonatal blood. Babies born at
later gestation had significantly higher levels of IgG1 and IgG4.
For IgG4 this appears to have been facilitated by significantly
higher levels of IgG4 in the mothers, that was then passed to
the fetus, rather than an increase in the rate of transplacental
transfer (which was unchanged). For IgG1, maternal levels were
no different with later gestation, and following adjustment for
other associated variables, gestation was also not associated with
the IgG1 transfer ratio. This suggests that the higher IgG1 at
later gestation may reflect an accumulation of IgG1 in the fetal
circulation over time, rather than an increased ability of the
placenta to transfer IgG in the last weeks of term pregnancy.
Several other studies have found a positive association between
total IgG and antigen-specific IgG and gestation (11, 30–32).
The main difference is that we studied healthy term (>37weeks)
pregnancies, unlike other studies which looked at the effect
of prematurity. Our study shows that even at term, every
additional weeks’ delay in delivery increases neonatal levels of
IgG1 and IgG4.
Birth centiles were negatively correlated with neonatal levels
of total IgG and of IgG2. This does not appear to be related
to a change in maternal levels, nor lower transfer ratio of these
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TABLE 4 | Unadjusted effects of clinical parameters on log(2) maternal to fetal IgG transfer ratios using simple linear regression based on n = 106 for total IgG and n =
116 for IgG subclasses.
Variable Antibody Coefficient Standard error p-value 95% CI
Maternal age
(years)
Total 0.012 0.009 0.189 −0.006, 0.029
IgG1 −0.001 0.012 0.920 −0.025, 0.022
IgG2 0.001 0.013 0.918 −0.025, 0.028
IgG3 0.002 0.009 0.825 −0.015, 0.019
IgG4 0.004 0.018 0.835 −0.031, 0.039
Maternal BMI Total −0.005 0.010 0.593 −0.025, 0.014
IgG1 −0.007 0.013 0.628 −0.033, 0.020
IgG2 0.001 0.015 0.932 −0.029, 0.031
IgG3 −0.013 0.010 0.200 −0.032, 0.007
IgG4 −0.020 0.020 0.319 −0.060, 0.020
Maternal ethnicity
(white = 0; non–white = 1)
Total −0.123 0.084 0.147 −0.289, 0.044
IgG1 −0.208 0.111 0.064 −0.429, 0.012
IgG2 −0.120 0.127 0.344 −0.371, 0.131
IgG3 −0.234 0.081 0.004 −0.394, −0.074
IgG4 0.106 0.168 0.530 −0.228, 0.440
Parity
(primiparous = 0; parous = 1)
Total −0.190 0.083 0.023 −0.354, −0.026
IgG1 −0.376 0.107 0.001 −0.588, −0.163
IgG2 −0.226 0.125 0.074 −0.474, 0.022
IgG3 −0.264 0.080 0.001 −0.422, −0.105
IgG4 −0.298 0.166 0.076 −0.627, 0.032
Rhesus status
(negative = 0; positive = 1)
Total −0.002 0.143 0.990 −0.285, 0.281
IgG1 0.094 0.171 0.583 −0.244, 0.432
IgG2 0.378 0.189 0.048 0.003, 0.752
IgG3 0.103 0.126 0.417 −0.147, 0.352
IgG4 0.435 0.252 0.087 −0.064, 0.934
Gestation at delivery
(weeks)
Total 0.110 0.035 0.002 0.041, 0.179
IgG1 0.099 0.048 0.040 0.005, 0.193
IgG2 0.104 0.054 0.055 −0.002, 0.210
IgG3 0.086 0.035 0.015 0.017, 0.155
IgG4 0.084 0.072 0.245 −0.058, 0.226
Sex of baby
(male = 0; female = 1)
Total 0.075 0.083 0.368 −0.090, 0.241
IgG1 −0.047 0.111 0.675 −0.267, 0.174
IgG2 −0.102 0.125 0.415 −0.350, 0.145
IgG3 0.001 0.082 0.994 −0.162, 0.164
IgG4 −0.099 0.166 0.554 −0.428, 0.230
Individualized birth ratio
(IBC)
Total −0.000 0.001 0.764 −0.003, 0.003
IgG1 −0.004 0.002 0.032 −0.008, −0.000
IgG2 −0.003 0.002 0.151 −0.008, 0.001
IgG3 −0.001 0.001 0.716 −0.003, 0.002
IgG4 −0.007 0.003 0.015 −0.013, −0.001
Tdap maternal vaccination status
(non-vacc = 0; vacc = 1)
Total 0.063 0.085 0.462 −0.106, 0.232
IgG1 −0.150 0.113 0.188 −0.375, 0.074
IgG2 −0.131 0.128 0.310 −0.384, 0.123
IgG3 0.028 0.084 0.743 −0.139, 0.195
IgG4 −0.157 0.170 0.358 −0.494, 0.180
Tdap maternal vaccination timing
(gestational weeks)
Total 0.034 0.018 0.063 −0.002, 0.069
IgG1 0.076 0.021 0.001 0.034, 0.118
IgG2 0.071 0.025 0.007 0.020, 0.122
IgG3 0.043 0.015 0.006 0.013, 0.073
IgG4 0.112 0.038 0.004 0.037, 0.187
(Continued)
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TABLE 4 | Continued
Variable Antibody Coefficient Standard error p-value 95% CI
Flu maternal vaccination status
(non-vacc = 0; vacc = 1)
Total −0.039 0.083 0.640 −0.204, 0.126
IgG1 −0.158 0.110 0.154 −0.377, 0.060
IgG2 0.057 0.125 0.650 −0.191, 0.305
IgG3 −0.002 0.082 0.985 −0.165, 0.161
IgG4 0.192 0.165 0.247 −0.135, 0.519
Flu maternal vaccination timing
(gestational weeks)
Total −0.009 0.008 0.270 −0.024, 0.007
IgG1 −0.005 0.011 0.619 −0.027, 0.017
IgG2 −0.018 0.010 0.076 −0.039, 0.002
IgG3 −0.017 0.006 0.013 −0.030, −0.004
IgG4 −0.002 0.007 0.750 −0.016, 0.012
Bold values indicate p value < 0.05.
FIGURE 6 | Correlation between gestation at Tdap vaccination and placental transfer of total IgG and IgG subclasses. (A) Correlation between the gestation that
pregnant women received the Tdap vaccine and the maternal to fetal IgG transfer ratio for total IgG and IgG subclasses [log(2) Y-axis]. Analysis was performed on
log(2) transformed ratios by Spearman’s rank correlation coefficient, and resultant p values are stated in the bottom right corner of each plot. Coefficients: Total IgG:
0.242, IgG1: 0.316, IgG2: 0.171, IgG3: 0.353, and IgG4: 0.316. (B) Correlation between the gestation at vaccination and the antibody concentration in maternal
blood and cord blood at birth. Analysis performed on log-transformed data by Spearman’s rank correlation coefficient. All correlations non-significant at p > 0.05 level.
Lines indicate simple linear regression. Coefficients for maternal IgG: Total IgG: −0.044; p = 0.752, IgG1: −0.145; p = 0.262, IgG2: −0.180; p = 0.161, IgG3: 0.013;
p = 0.919, IgG4: 0.029; p = 0.823. Coefficients for cord IgG: Total IgG: 0.235; p = 0.079, IgG1: 0.197; p = 0.125, IgG2: 0.134; p = 0.296, IgG3: 0.164; p = 0.199,
and IgG4: 0.191; p = 0.133. N = 63.
subclasses, neither of which were associated with birth centiles.
The reason for this is unclear, but it could be an effect of higher
hemodilution of IgG in a larger fetal circulation. It would be
difficult to explore this; perhaps an analysis that incorporated
both infant birth centiles and placental weight could shed light
on this observation. Unfortunately, we did not record placental
size nor weight in this current study.
Babies born to rhesus negative mothers had significantly lower
levels of IgG2. These mothers were given injections of anti-D
IgG at 28 weeks gestation. There appeared to be no difference
in maternal levels of IgG at birth, but there were significantly
lower transfer ratios of IgG2 (but not of any other subclass). This
suggests that the administered IgG could compete with transfer
of endogenous IgG2, but a much larger cohort of rhesus negative
pregnancies is required to study this further. There may be a
benefit to ensuring a time interval between maternal vaccination
and anti-D infusion, if IgG2 is important for protection, and
maternal vaccination studies should include Rhesus status in
their analyses.
Some maternal factors were associated with changes in
maternal IgG levels and the maternal/cord transfer ratio, but
had no effect on final IgG levels in the neonate. Non-white
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TABLE 5 | Adjusted effects of clinical parameters on maternal and cord antibody levels, and transfer ratios using multiple linear regression based on n = 106 for total IgG
and n = 116 for IgG subclasses.
Outcome Covariates Coefficient Standard error p-value 95% CI
Maternal IgG
Total IgG Parity 0.166 0.067 0.015 0.033, 0.297
Maternal age −0.016 0.007 0.018 −0.027, −0.003
Gestation at delivery −0.128 0.080 0.110 −0.286, 0.030
Ethnicity 0.054 0.066 0.413 −0.076, 0.185
Transfer ratio
Total IgG Gestation at delivery 0.096 0.036 0.008 0.025, 0.166
Parity −0.135 0.083 0.105 −0.299, 0.029
IgG1 Parity −0.312 0.110 0.006 −0.530, −0.093
IBC −0.003 0.002 0.115 −0.007, 0.001
Gestation at delivery 0.064 0.047 0.170 −0.028, 0.157
IgG3 Ethnicity −0.207 0.081 0.012 −0.366, −0.047
Gestation at delivery 0.072 0.035 0.041 0.003, 0.140
Covariates: Parity: primiparous = 0, parous = 1; Maternal age: years; Gestation at delivery: weeks; Ethnicity: white = 0, non-white = 1.
IBC, individualized birth centile.
women had higher levels of IgG2 and IgG3, but the transfer
ratios were lower in these pregnancies and thus cord levels
were not significantly different. Older mothers had lower
total IgG levels, but there was no effect on transfer nor
cord levels. Interestingly, women who had previously had a
live birth had higher levels of total IgG and IgG1 at birth.
However, this was not reflected in neonatal blood, and the
transfer ratio between maternal and cord blood was reduced
in these pregnancies. Thus, as previously discussed, although
maternal and cord IgG levels are positively correlated, the
ability of the placenta to transfer IgG may be limited by
potential saturation of Fc transport receptors at higher IgG
concentrations. Previous studies found no effect of parity on the
transfer of antigen-specific IgG in placental malaria nor HIV
infection (36, 38), nor on cord blood antigen-specific antibody
concentrations (39). The only other subclass transfer study
relating to malaria and hypergammaglobulinemia also reported
no effect of parity (17).
Finally, we investigated the impact of maternal vaccination on
levels and transfer of IgG subclasses. Tdap vaccination status had
no impact on maternal nor cord IgG concentrations. However,
there was a positive correlation between later gestation at Tdap
vaccination and higher transfer ratios of all four subclasses. This
finding is of interest given that the recommended gestation for
maternal Tdap/IPV vaccination has undergone several changes
in the UK, partly as a result of studies showing that earlier
vaccination results in higher anti-Tdap antibodies in infants.
For example, a study by Eberhardt et al. (40) propose that the
best cord blood levels of anti-Tdap antibodies occur when the
vaccine is given between 26 and 29 weeks. However, despite this
observation, the timing of Tdap/IPV was not associated with any
significant changes in total/subclass IgG levels in cord blood,
suggesting limited impact on bulk concentrations of IgG in the
neonate. Perhaps more intriguing is our observation that babies
born to influenza vaccinated mothers have significantly higher
levels of IgG4. Vaccinated mothers also have higher IgG4 levels,
which is interesting given that pregnancy has been previously
associated with an elevated IgG4 response to seasonal influenza
vaccine (41). We have previously shown that timing of influenza
vaccination impacts on anti-influenza levels in babies, with the
highest levels if mothers were vaccinated 4–24 weeks before
delivery (42), but here we find no effect of influenza vaccine
timing on neonatal levels nor transfer of the IgG subclasses.
In summary, the current study provides a detailed analysis
and update on the transplacental transfer of IgG subclasses,
including a review of 17 previous studies investigating maternal
to fetal transfer of IgG subclasses. Most studies agree that IgG1
is the most efficiently transferred antibody subclass, with lower
transfer of IgG2–4. We conclude that transfer of the IgG2–
4 subclasses varies widely between study populations, but that
IgG2 transfer may not be as poor as often stated. The diverse
findings between studies could be due to differences in ethnicity,
parity, vaccination status (including gestation of vaccination),
gestation at delivery (even within term delivery populations)
and birth centiles between study populations; clinical parameters
that were associated with transfer ratios of total IgG and IgG
subclasses from mother to fetus in our study. It is important
that we continue to offer maternal vaccination to all women.
Parous women, and those of non-white ethnicities may have
reduced antibody transfer, and it may therefore be particularly
important to engage with these demographic groups; we have
previously reported maternal Tdap vaccination rates in our
setting to be 36% lower in black women compared to white
women (43). Encouragingly, neonatal levels of total IgG and
IgG subclasses seems largely unaffected by maternal factors.
However, administration of anti-D may result in lower IgG2
levels in the neonate, and maternal flu vaccination may result
in higher levels of IgG4. Therefore, the impact of both of these
interventions on the neonatal immune response should continue
to be explored.
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